ACE and hepatocellular carcinoma: In a study of three independent cohorts (Germany, Japan, and Hong Kong), GALAD demonstrated higher sensitivity and specificity in HCC diagnosis than AFP, AFP-L3, or DCP alone and is currently in clinical trials as a new HCC surveillance tool48.